rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
12
|
pubmed:dateCreated |
1993-3-5
|
pubmed:abstractText |
To determine the maximum tolerated dose of granulocyte-macrophage colony-stimulating factor (GM-CSF) that would reduce the severity and duration of neutropenia from combination cytotoxic chemotherapy in the treatment of AIDS-related Kaposi's sarcoma (KS).
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0269-9370
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
6
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1477-81
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:1283520-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:1283520-Adult,
pubmed-meshheading:1283520-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1283520-Bleomycin,
pubmed-meshheading:1283520-Cytokines,
pubmed-meshheading:1283520-Doxorubicin,
pubmed-meshheading:1283520-Drug Administration Schedule,
pubmed-meshheading:1283520-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:1283520-HIV Antigens,
pubmed-meshheading:1283520-HIV Core Protein p24,
pubmed-meshheading:1283520-Humans,
pubmed-meshheading:1283520-Leukocyte Count,
pubmed-meshheading:1283520-Neutropenia,
pubmed-meshheading:1283520-Recombinant Proteins,
pubmed-meshheading:1283520-Sarcoma, Kaposi
|
pubmed:year |
1992
|
pubmed:articleTitle |
Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi's sarcoma.
|
pubmed:affiliation |
Department of Internal Medicine, University of Southern California School of Medicine, Los Angeles.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|